Ovarian cancer is an immunogenic tumour, and immunotherapy is a potential treatment for ovarian cancer [6], where the overall objective remission rate of anti-PD-1 antibody ranges from 10 to 15%, lower than that observed in other cancer types [7, 8]. Here, PDCD1 is linked to ovarian carcinoma.